Citations

Clear

37 citation(s) found for "Thomas, Colleen".

Simulation: An Effective Method of Teaching Cosmetic Botulinum Toxin Injection Technique
Mitkov, Mario , Thomas, Colleen S. , Cochuyt, Jordan J., Forte, Antonio J. , Mitkov, Mario V., Forte, Antonio Jorge , Perdikis, Galen

Mayo Clinic

Aesthetic Surgery Journal | July 3, 2018 | Volume: 38 | Issue: 12 | Pages: NP207-NP212

10.1093/asj/sjy159 | PMID 29982282 Get It

Patient portal use and hospital outcomes
Burton, M. Caroline , Dawson, Nancy L. , Thomas, Colleen S. , Nordan, Lisa, Greig, Hope E, Aljabri, Duaa , Naessens, James M. , Dumitrascu, Adrian G, Nordan, Lisa M, Aljabri, Duaa I, Dumitrascu, Adrian

Mayo Clinic

Journal of the American Medical Informatics Association | December 1, 2017 | Volume: 25 | Issue: 4 | Pages: 447-453

10.1093/jamia/ocx149 | PMID 29300961 Get It

Abstract Objectives To determine whether use of a patient portal during hospitalization is associated with improvement in hospital outcomes, 30-day readmissions, inpatient mortality, and 30-day mortality. Materials and Methods We performed a retrospective propensity score–matched study that included all adult patients admitted to Mayo Clinic Hospital in Jacksonville, Florida, from August 1, 2012, to July 31, 2014, who had signed up for a patient portal account prior to hospitalization (N = 7538). Results Out of the admitted patients with a portal account, 1566 (20.8%) accessed the portal while in the hospital. Compared to patients who did not access the portal, patients who accessed the portal were younger (58.8 years vs 62.3 years), had fewer elective admissions (54.2% vs 64.1%), were more frequently admitted to medical services (45.8% vs 35.2%), and were more likely to have liver disease (21.9% vs 12.9%) and higher disease severity scores (0.653 vs 0.456). After propensity score matching, there was no statistically significant difference between the 2 cohorts with respect to 30-day readmission (P = .13), inpatient mortality (P = .82), or 30-day mortality (P = .082). Conclusion Use of the patient portal in the inpatient setting may not improve hospital outcomes. Future research should examine the association of portal use with more immediate inpatient health outcomes such as patient experience, patient engagement, medication reconciliation, and prevention of adverse events.
[P3–356]: VENTRICULOMEGALY IS A BIOMARKER OF GAIT AND COGNITIVE DECLINE
Graff‐Radford, Neill R. , Gunter, Jeffrey L. , Thomas, Colleen S. , Graff‐Radford, Jonathan , Petersen, Ronald C. , Crook, Julia E. , Jones, David T. , Boeve, Bradley F. , Knopman, David S. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | October 20, 2017 | Volume: 13 | Issue: 7S_Part_22 | Pages: No page available

10.1016/j.jalz.2017.06.1572 Get It

Intra‐operative predictors of postoperative Takotsubo syndrome in liver transplant recipients—An exploratory case‐control study
Aniskevich, Stephen , Peiris, Prith, Taner, Cemal Burcin, Torp, Klaus L., Thomas, Colleen S. , Yataco, Maria, Pai, Sher‐Lu , Yataco, Maria L, Pai, Sher-Lu , Aniskevich, Stephen , Chadha, Ryan , Torp, Klaus D.

Mayo Clinic

Clinical Transplantation | August 22, 2017 | Volume: 31 | Issue: 11 | Pages: No page available

10.1111/ctr.13092 | PMID 28833618 Get It

AbstractIntroductionTakotsubo syndrome (TTS), also known as Takotsubo cardiomyopathy or stress‐induced cardiomyopathy, has been described following a variety of surgeries and disease states. The relationship between intra‐operative anesthesia management and the development of this syndrome has never been fully elucidated.ObjectivesThe primary objective of this study was to determine the relationship of multiple intra‐operative factors on the pathogenesis of TTS.MethodsA single‐center retrospective review of all liver transplants performed at Mayo Clinic Florida from January 2005 to December 2014. Patients developing left ventricular dilation and a concomitant decrease in ejection fraction, a negative cardiac catheterization, or stress test within 30 days of transplantation were identified. Cases were matched 2:1 to controls with respect to MELD, age, sex, and indication for transplantation. Our evaluation included liver graft characteristics, intra‐operative medications, and intra‐operative hemodynamic measurements.ResultsWe identified 24 cases of TTS from a pool of 1752 transplants, for an incidence of 1.4%. No statistically significant differences in intra‐operative measures between the two groups were identified (all P ≥ .08).ConclusionOur exploratory, single‐center retrospective review evaluating 46 intra‐operative characteristics found no association with the development of TTS.
The safety and tolerability of inhaled treprostinil in patients with pulmonary hypertension and chronic obstructive pulmonary disease
Shujaat, Adil , Thomas, Colleen S. , Rahaghi, Franck , Bajwa, Abubakr A. , Patel, Minal R. , Burger, Charles D.

Mayo Clinic

Pulmonary Circulation | October 5, 2016 | Volume: 7 | Issue: 1 | Pages: 82-88

10.1086/689291 | PMID 28680567 Get It

The primary aim was to explore the safety and tolerability of inhaled treprostinil when used in patients with pulmonary hypertension (PH) with concomitant chronic obstructive pulmonary disease (COPD). Patients with a diagnosis of pre‐capillary PH (defined as pulmonary artery mean pressure of ≥ 25 mmHg and pulmonary artery wedge pressure or left ventricular end diastolic pressure of ≤ 15 mmHg) who were being initiated on inhaled treprostinil and had concomitant COPD (defined as FEV1/FVC ratio ≤ 70% with FEV1 ≥ 40% predicted) were considered for inclusion in this pilot study. Assessments included adverse events, physical exam, World Health Organization (WHO) functional class, 6‐minute walk test (6MWT), modified Borg dyspnea score, and concomitant medication. At baseline and week 16 St. George’s Respiratory Questionnaire (SGRQ), arterial blood gas (ABG), and pulmonary function test (PFT) were assessed. The median age was 65 years (age range, 56–80 years) and five patients (56%) were men. Among the nine patients, a majority had an increase in 6MWT from baseline to week 16 (median change, 19 m). Only three of the nine patients (33%) had an increase in A‐a gradient at week 16 (median change, –7). There was no difference in any of the following: arterial blood gases, WHO functional class, 6MWT results, or SGRQ scores from baseline to week 16. There was a statistically significant decline in several of the PFT measures, including FEV1 (median change, –0.18 L; P = 0.004; median change, –7% of predicted; P = 0.016), FVC (median change, –0.23 L; P = 0.027), and diffusion capacity for carbon monoxide (DLCO) (median change, –5% of predicted; P = 0.023). The small number of patients limits firm conclusions; however, inhaled treprostinil did not seem to adversely impact oxygenation in the majority of the study patients with pre‐capillary PH and COPD. While there may have an adverse impact on some pulmonary function parameters, the clinical significance is unclear.
von Willebrand Factor Abnormalities and Heyde Syndrome in Dysfunctional Heart Valve Prostheses
Blackshear, Joseph L., McRee, Chad, Safford, Robert E. , Pollak, Peter , Stark, Mark E., Thomas, Colleen S. , Rivera, Candido E., Wysokinska, Ewa , Chen, Dong , McRee, Chad W, Pollak, Peter M, Chen, Dong

Mayo Clinic

JAMA Cardiology | April 6, 2016 | Volume: 1 | Issue: 2 | Pages: 198

10.1001/jamacardio.2016.0075 | PMID 27437891 Get It

Prevalence of metabolic syndrome in patients with pulmonary hypertension
Ussavarungsi, Kamonpun , Thomas, Colleen S. , Burger, Charles D.

Mayo Clinic

The Clinical Respiratory Journal | October 23, 2015 | Volume: 11 | Issue: 6 | Pages: 721-726

10.1111/crj.12406 | PMID 26493968 Get It

AbstractBackground and AimsTo determine the prevalence of metabolic syndrome (MetS) – a potential phenotypical risk for pulmonary hypertension (PH) – in patients with PH and by PH diagnostic group including group 1 pulmonary arterial hypertension (PAH); group 1.1 idiopathic PAH, groups 1.2 heritable PAH, 1.3 drug and toxin induced, 1.4 associated PAH, group 2 PH with left heart disease, group 3 PH associated with lung disease and/or hypoxemia, group 4 PH owing to chronic thrombotic and/or embolic disease, and group 5 PH from multifactorial mechanisms.MethodsWe conducted a retrospective chart review of patients referred to Mayo Clinic in Florida from January 1990 to October 2013 (N = 1287). Only patients whom PH was confirmed by right heart catheterization were included (N = 640). MetS was defined with at least three of the following: systemic hypertension, diabetes mellitus, hyperlipidemia and body mass index > 30.ResultsMetS was prevalent in 247 of 640 (39%) with PH: 13% in group 1.1 PAH, 12% in groups 1.2–1.4 PAH, 54% in group 2, 55% in group 3, 23% in group 4 and 24% in group 5. After adjusting for age, sex and race, diagnostic subgroup analysis revealed a higher prevalence of MetS in WHO Group 2 PH patients [adjusted odd ratios (OR): 2.58, P < 0.0001] and WHO group 3 PH (adjusted OR: 2.77, P < 0.0001) when compared to group 1 PH.ConclusionThe prevalence of MetS was observed in 39% of patients with PH; however, among PH patients, the prevalence was higher in group 2 and 3 PH.
Clinical and Molecular Features of Hürthle Cell Carcinoma of the Thyroid
Chindris, Ana-Maria, Casler, John D., Bernet, Victor , Rivera, Michael , Thomas, Colleen, Kachergus, Jennifer M., Necela, Brian M. , Westphal, Sydney A., Grant, Clive S., Thompson, Geoffrey B. , Schlinkert, Richard T., Thompson, E. Aubrey , Smallridge, Robert C., Chindris, Ana-Maria , Hay, Ian

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | September 26, 2014 | Volume: 100 | Issue: 1 | Pages: 55-62

10.1210/jc.2014-1634 | PMID 25259908 Get It

Abstract Context: Hürthle cell cancer (HCC) of the thyroid remains the subject of controversy with respect to natural course, treatment, and follow-up. Objective: The objective of the study was to evaluate the clinical and molecular features associated with outcome in HCC. Design: The study was a review of 173 HCC cases treated at Mayo Clinic over 11 years with a median 5.8-year follow-up. Results: None of the patients with minimally invasive histology had persistent disease, clinical recurrence, or disease-related death. Male gender and TNM stage were independently associated with increased risk of clinical recurrence or death in widely invasive patients. The 5-year cumulative probability of clinical recurrence or death was higher in patients with TNM stage III–IV (females, 74%; males, 91%) compared with patients with TNM stage I–II (females, 0%; males, 17%). Pulmonary metastases were best identified by computed tomography, whereas radioactive iodine scans were positive in only two of 27 cases. Thyroglobulin was detectable in patients with clinical disease, with the notable exception of five patients with distant metastases. The common TERT C228T promoter mutation was detected in both widely invasive and minimally invasive tumors. TERT mRNA was below the limit of detection in all samples. Conclusion: Widely invasive HCC with TNM stage III–IV is aggressive, with low probability of recurrence-free survival. Males have worse outcomes than females. Minimally invasive HCC appears to be considerably less aggressive. Radioactive iodine scan performs poorly in detecting distant disease. Although the TERT gene is mutated in HCC, the role of this mutation remains to be demonstrated.
ARE PLASMA Aβ MEASURES ASSOCIATED WITH LONGITUDINAL CHANGE IN HIPPOCAMPAL VOLUME?
Graff‐Radford, Neill R. , Thomas, Colleen S. , Younkin, Linda H., Petersen, Ronald C. , Younkin, Steven G. , Crook, Julia E. , Knopman, David S. , Boeve, Bradley F. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | September 6, 2014 | Volume: 10 | Issue: 4S_Part_5 | Pages: No page available

10.1016/j.jalz.2014.04.439 Get It

Tacrolimus dosage requirements in lung transplant recipients receiving antifungal prophylaxis with voriconazole followed by itraconazole: a preliminary prospective study
Enderby, Cher Y. , Thomas, Colleen S. , Keller, Cesar A., Heckman, Michael G.

Mayo Clinic

Clinical Transplantation | June 16, 2014 | Volume: 28 | Issue: 8 | Pages: 911-915

10.1111/ctr.12403 | PMID 24931421 Get It

AbstractBackgroundConcomitant administration of the triazole antifungals, voriconazole or itraconazole, with tacrolimus can result in significant drug interaction in the transplant recipient. Limited published information exists regarding tacrolimus dosing when transitioning from voriconazole to itraconazole. The objective of this study was to evaluate the extent of the drug interaction with antifungal prophylaxis using voriconazole followed by a change to itraconazole in lung transplant recipients receiving tacrolimus.MethodsThis prospective study included lung transplant recipients receiving antifungal prophylaxis with voriconazole followed by a switch to itraconazole. Patients were followed from the time of transplant until two months after converting to itraconazole. All patients received standard immunosuppression with tacrolimus, mycophenolate mofetil, and a corticosteroid. Tacrolimus dose normalized concentrations using concentration/dose ratio were compared while receiving voriconazole versus itraconazole.ResultsTwenty lung transplant recipients were included in the final analysis. No difference was found with the tacrolimus dose normalized concentrations on voriconazole 254 ± 28 (ng/mL)/(mg/kg) compared with itraconazole 234 ± 34 (ng/mL)/(mg/kg), p = 0.65.ConclusionTacrolimus dosage adjustments were not necessary when converting from voriconazole to itraconazole. Validation in a larger population is needed to confirm these findings.